University at Buffalo paper urges shift to a cannabis public health approach across U.S.
Researchers call for harm reduction, education and standardized policy as cannabis regulation outpaces public health systems.
A University at Buffalo study published in the American Journal of Public Health urges a decisive shift toward a cannabis public health approach as legalization spreads across the United States. The paper, led by Daniel J. Kruger, PhD, warns that millions of people use cannabis for health reasons with little clinical oversight and scarce reliable information about product risks and dosing. The authors argue that current policy, long shaped by politics rather than science, leaves public health systems unprepared to manage the real-world consequences of broader access.
Study urges public-health framing for cannabis policy
The UB researchers say cannabis policy should move from abstinence-focused and punitive models to frameworks grounded in public health principles. Their paper recommends adopting the social ecological model to account for individual behavior, product characteristics, community norms, and regulatory environments. The authors contend that such a framework would better identify points to reduce harm and promote health within rapidly changing markets.
The study’s lead author, Kruger, frames legalization as a growing force that public health must engage with proactively. He warns that without a public-health oriented strategy, efforts to limit harms will be inconsistent and ineffective across jurisdictions.
Authors call for harm reduction and public education
A central recommendation from the paper is stronger public education about cannabis, including information on potency, dosing, and delayed effects from edibles. The researchers note that many therapeutic users do not disclose their cannabis use to clinicians, leaving a gap in medical oversight and risk mitigation. They recommend targeted campaigns and clinical outreach to help users make safer choices and to reduce incidents of overdose-type reactions such as anxiety or panic from excess dosing.
Harm-reduction measures should include clear labeling and dosing guidance, accessible resources for primary care providers, and community-level interventions tailored to diverse user populations. The paper also cites the National Academies’ recent report calling for improved public communication on cannabis benefits and risks.
Cannabinoid complexity complicates regulation
The report highlights a fundamental difficulty for regulators: cannabis is not a single product like alcohol but a complex mixture of hundreds of psychoactive compounds. The researchers argue that policy should account for differences between cannabinoids rather than treating all cannabis products the same. Modeling cannabinoids individually, they write, is essential to understand both therapeutic potential and distinct safety profiles.
That scientific complexity, the authors say, makes single-policy approaches insufficient and increases the need for robust, cannabinoid-specific research funding and surveillance.
Patchwork of state rules raises safety concerns
UB researchers point to the fragmented regulatory landscape as a major obstacle to safeguarding public health. With federal classification still set at Schedule I, states have developed disparate rules that can create inconsistencies in product standards and enforcement. The paper warns that products can cross state lines and encounter entirely different regulatory regimes, increasing the likelihood of uneven quality and unclear consumer protections.
Even where regulated dispensaries exist, many users continue to obtain cannabis through illegal channels, the study notes, complicating efforts to track usage patterns and intervene when products pose risks.
THC‑O example underscores information gaps and hazards
The authors use THC‑O as a case study to illustrate how limited data can heighten risk. They explain that while vaporizing or ingesting some products is often recommended as a harm-reduction tactic, THC‑O vaporization may generate ketene, a toxic gas linked to severe lung injury. That example, the paper says, demonstrates how conventional harm-reduction advice can be unsafe for specific compounds when scientific evidence is incomplete.
This gap in authoritative information, the researchers argue, increases the urgency for product testing requirements, transparent labeling, and public guidance that reflects compound-specific risks.
Rescheduling debate and research barriers
The study notes recent signals from U.S. regulatory agencies about the possibility of moving cannabis from Schedule I to Schedule III as a potentially constructive development. Rescheduling could reduce research barriers and enable more coordinated federal policies, the authors say, which in turn might support national standards for product safety, potency labeling, and clinical trials.
Kruger and colleagues stress that filling evidence gaps will require a spectrum of research methods beyond clinical trials, including observational studies and surveillance of real-world use and outcomes.
The work, authored by Daniel J. Kruger, Jessica S. Kruger and Carlton CB Bone, was published without external funding and urges public-health institutions to treat cannabis as a complex, population-level issue.
Public-health officials, clinicians and lawmakers now face the task of translating the paper’s recommendations into practice as legalization continues to expand. The researchers urge immediate investment in education, surveillance, and regulatory alignment to protect users and communities while allowing for the potential benefits of controlled access to cannabis.
